1. Towards a Model-Based Dose Recommendation for Doxorubicin in Children

   • Swantje Völler
   • Georg Hempel
   • Joachim Boos

   Current Opinion Open access 19 September 2016 Pages: 215 - 223

   

2. Bioequivalence Evaluations of Generic Dry Powder Inhaler Drug Products: Similarities and Differences Between Japan, USA, and the European Union

   • Ryosuke Kuribayashi
   • Toru Yamaguchi
   • Kazunori Takagi

   Review Article 26 July 2016 Pages: 225 - 233

3. Clinical Pharmacokinetics and Pharmacodynamics of Afatinib

   • Sven Wind
   • David Schnell
   • Peter Stopfer

   Review Article Open access 28 July 2016 Pages: 235 - 250

   

4. Clinical Pharmacokinetics and Pharmacodynamics of Safinamide

   • Thomas Müller
   • Paul Foley

   Review Article 24 September 2016 Pages: 251 - 261

   

5. A Strategy for Dosing Vancomycin to Therapeutic Targets Using Only Trough Concentrations

   • John P. Prybylski

   Original Research Article 07 July 2016 Pages: 263 - 272

   

6. Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?

   • Elisa A. M. Calvier
   • Elke H. J. Krekels
   • Catherijne A. J. Knibbe

   Original Research Article Open access 10 August 2016 Pages: 273 - 285

   

7. Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients

   • Sheima Farag
   • Remy B. Verheijen
   • Neeltje Steeghs

   Original Research Article 19 July 2016 Pages: 287 - 292

   

8. Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients

   • Huixin Yu
   • Nielka van Erp
   • Alwin D. R. Huitema

   Original Research Article 17 August 2016 Pages: 293 - 303

   

9. Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure

   • Sander Bins
   • Karel Eechoute
   • Ron H. J. Mathijssen

   Short Communication Open access 26 July 2016 Pages: 305 - 310

   

10. Comment on: “Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients: Is Augmented Renal Clearance What We Really Want to Know? Some Suggested Management Approaches and Clinical Software Tools”

    • Johannes H. Proost

    Commentary 15 December 2016 Pages: 311 - 312

11. Author’s Reply to Proost: “Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients”

    • Roger W. Jelliffe

    Reply 29 December 2016 Pages: 313 - 316